Medicine
Enspryng 180 mg/1.5 mL injection
Enspryng 180 mg/1.5 mL injection is a prescription medicine containing Satralizumab for subcutaneous use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from…
Key facts
- Active ingredient (INN)
- Satralizumab
- Brand
- Enspryng
- Strength
- 180 mg/1.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1.5 mL
- Marketing authorisation holder
- Genentech
- Manufacturer
- Genentech
- Origin register
- US FDA, United States
- Storage
- Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. ENSPRYNG can be stored out of refrigeration for a maximum of 8 days at a temperature that does not exceed 30°C (86°F). If ENSPRYNG is removed from and returned to the refrigerator, the total combined time out of refrigeration should not exceed 8 days. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC Immunosuppressive drug, subgroup L04AC
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 October 2026
- Identifiers
- RxCUI 2391555, 2391560, 2755191 +1DailyMed set ID 64c156a4-9bad-4d45-a294-0733c141f47bNDC 50242-005Application BLA761149
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, plastic in 1 carton / 1.5 mL in 1 syringe, plastic | 50242-005-01 | Genentech | 15 October 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Satralizumab
Clinical summary
Satralizumab is a prescription medicine indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Satralizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SatralizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Enspryng prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Enspryng: European public assessment report (EPAR) · European Medicines Agency
Need Enspryng 180 mg/1.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.